Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a rare liver disease characterized by inflammation and scarring of the bile ducts, which can lead to liver damage and complications.
Primary Sclerosing Cholangitis: Norucholic Acid Tablets
We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have any active cancer or malignant disease?
- Are you currently pregnant or breastfeeding?
- Do you have a history of heavy alcohol consumption (more than 30 grams per day for men or more than 20 grams per day for women)?
- Do you have severe kidney problems or liver cirrhosis?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Norucholic Acid
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Graz
Department of Internal Medicine, Division of Gastroenterology and Hepatology
Graz, Austria
Medical University Of Vienna
Klin. Abt. für Gastroenterologie und Hepatologie
Vienna, Austria
UZ Leuven
Gastroenterology and Hepatology
Heverlee, Belgium
Sponsor: Dr. Falk Pharma GmbH
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.